You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

(177)Lu-DOTA-EB-TATE

Showing 1 - 25 of 505
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors Trial in New York (177Lu-DOTA-EB-TATE, Amino Acid Solution)

Recruiting
  • Neuroendocrine Tumors
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 22, 2022

Glioblastoma Trial in France, Portugal, Spain ([177Lu]Lu-DOTA-TATE, [68Ga]Ga-DOTA-TATE, Temozolomide)

Recruiting
  • Glioblastoma
  • Bron, France
  • +8 more
Jan 23, 2023

Extensive Stage Small Cell Lung Cancer Trial in France ([177Lu]Lu-DOTA-TATE, Tislelizumab, [68Ga]Ga-DOTA-TATE)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Lille, France
  • +6 more
Jan 23, 2023

Refractory Solid Tumor Trial in Xiamen (177Lu-DOTA-EB-FAPI radionuclide therapy)

Recruiting
  • Refractory Solid Tumor
  • 177Lu-DOTA-EB-FAPI radionuclide therapy
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 26, 2023

Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)

Active, not recruiting
  • Neuroendocrine Carcinoma
  • Lu-DOTA-TATE
  • London, Ontario, Canada
    London Health Sciences Centre
Apr 5, 2022

Metastatic Malignant Tumor in the Viscera, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic

Not yet recruiting
  • Metastatic Malignant Neoplasm in the Viscera
  • +4 more
  • Lutetium Lu 177 Dotatate
  • (no location specified)
Jan 25, 2023

Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

Recruiting
  • Refractory Thyroid Gland Carcinoma
  • +3 more
  • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 3, 2022

Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)

Not yet recruiting
  • Metastatic Neuroendocrine Tumor
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Feb 10, 2023

Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Tumor, Stage III Pancreatic Neuroendocrine Tumor AJCC v8 Trial

Not yet recruiting
  • Metastatic Pancreatic Neuroendocrine Tumor
  • +4 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Jan 14, 2023

Neuroendocrine Tumor Trial in United States (Lutetium Lu 177 Dotatate, Peposertib)

Recruiting
  • Neuroendocrine Neoplasm
  • Biospecimen Collection
  • +4 more
  • Duarte, California
  • +3 more
Jan 12, 2023

Non-hodgkin Lymphoma Trial (CD38-SADA:177Lu-DOTA Complex)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • CD38-SADA:177Lu-DOTA Complex
  • (no location specified)
Aug 15, 2023

Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,

Recruiting
  • Advanced Lung Carcinoid Tumor
  • +11 more
  • Boston, Massachusetts
  • +1 more
Jul 19, 2022

Metastatic Digestive System Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor Trial in United States (Lutetium Lu 177

Recruiting
  • Metastatic Digestive System Neuroendocrine Neoplasm
  • Metastatic Neuroendocrine Tumor
  • Phoenix, Arizona
  • +10 more
Aug 23, 2022

Metastatic Midgut Neuroendocrine Tumor, Unresectable Midgut Neuroendocrine Tumor Trial (procedure, drug, other)

Not yet recruiting
  • Metastatic Midgut Neuroendocrine Tumor
  • Unresectable Midgut Neuroendocrine Tumor
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Mar 16, 2023

Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma Trial in Rochester (radiation, drug, procedure, other)

Recruiting
  • Grade 1 Meningioma
  • +4 more
  • Gallium Ga 68-DOTATATE
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 11, 2023

Advanced Pancreatic Cancer and Cholangiocarcinoma Trial in Hangzhou (PRRT with 177Lu-EB-FAPI)

Recruiting
  • Advanced Pancreatic Cancer and Cholangiocarcinoma
  • PRRT with 177Lu-EB-FAPI
  • Hangzhou, Zhejiang, China
    First Affiliated Hospital of Zhejiang University
Oct 10, 2023

Neuroendocrine Tumors Trial in Beijing (177Lu-DOTA-EB-TATE 1, 177Lu-DOTA-TATE, 177Lu-DOTA-EB-TATE 2)

Unknown status
  • Neuroendocrine Tumors
  • 177Lu-DOTA-EB-TATE 1
  • +3 more
  • Beijing, China
    Peking Union Medical College Hospital
Jul 6, 2019

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
  • +2 more
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Nov 6, 2022

Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma Trial in Sacramento ([68Ga]Ga DOTA-5G and [177Lu]Lu

Recruiting
  • Metastatic Pancreatic Cancer
  • Locally Advanced Pancreatic Adenocarcinoma
  • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
  • Sacramento, California
    University of California Davis
Apr 21, 2022

Carcinoma, Neuroendocrine Trial in Edmonton ([177]Lu-DOTA-TATE)

Recruiting
  • Carcinoma, Neuroendocrine
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Apr 12, 2021

Prostate Cancer Trial in Beijing (2.0 GBq of 177Lu-EB-PSMA)

Recruiting
  • Prostate Cancer
  • 2.0 GBq of 177Lu-EB-PSMA
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jul 13, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Beijing (1.11GBq of 177Lu-EB-PSMA-617, 2.00 GBq of 177Lu-EB-PSMA-617,

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • 1.11GBq of 177Lu-EB-PSMA-617
  • +2 more
  • Beijing, China
    Peking Union Medical College Hospital
May 6, 2022

Gastroenteropancreatic Neuroendocrine Tumor Trial in Stanford (Lutathera, Gallium 68 Dotatate, Computed Tomography (CT))

Suspended
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Stanford, California
    Stanford Cancer Institute Palo Alto
Sep 21, 2022

177Lu-EB-FAPI Trial in Beijing (68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy)

Recruiting
  • 177Lu-EB-FAPI
  • 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
May 27, 2022

Metastatic Prostate Cancer Trial in Perth (177Lu-DOTA-rosopatamb)

Not yet recruiting
  • Metastatic Prostate Cancer
  • 177Lu-DOTA-rosopatamb
  • (no location specified)
Aug 29, 2022